Recent developments in myelofibrosis

Raoul Tibes, James M Bogenberger, Ruben A MesaDivision of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USAAbstract: The myeloproliferative neoplasm of myelofibrosis (MF) is clinically constituted by individuals both with primary MF, as well as those that evolved from an antecedent polycythe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mesa RA, Bogenberger JM, Tibes R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/080eaffa2590496f87c9e93a7f5c44ed
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:080eaffa2590496f87c9e93a7f5c44ed
record_format	dspace
spelling	oai:doaj.org-article:080eaffa2590496f87c9e93a7f5c44ed2021-12-02T06:31:13ZRecent developments in myelofibrosis1179-9889https://doaj.org/article/080eaffa2590496f87c9e93a7f5c44ed2012-07-01T00:00:00Zhttp://www.dovepress.com/recent-developments-in-myelofibrosis-a10273https://doaj.org/toc/1179-9889Raoul Tibes, James M Bogenberger, Ruben A MesaDivision of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USAAbstract: The myeloproliferative neoplasm of myelofibrosis (MF) is clinically constituted by individuals both with primary MF, as well as those that evolved from an antecedent polycythemia vera or essential thrombocythemia. Individuals presenting with MF have a heterogeneous phenotype which can involve significant constitutional symptoms (night sweats, fevers, weight loss, fatigue, variable but frequently problematic splenomegaly, and multifactorial cytopenias). These individuals clearly have decreased survival. Refinement of MF prognostic scores can distinguish from survival as poor as 16 months, to a median survival of 185 months. Sadly, although curative, allogeneic stem cell transplant still has sobering success rates for individuals of the standard ages for MF. Recent reports suggest less than half of patients will be alive at 3 years after allotransplant above the age of 60 years. The most important recent advancement in MF therapy has been the development of Janus kinase 2 (JAK2) inhibitors led by ruxolitinib, now Food and Drug Administration approved in the United States, and several other JAK2 inhibitors (in testing) including SAR302503, CYT387, and SB1518. In randomized, placebo-controlled studies, ruxolitinib was demonstrated to be superior for the improvement of splenomegaly and symptoms. These benefits are mirrored across other JAK2 inhibitors. Improving anemia remains an unmet need in MF and is currently being evaluated by clinical trials utilizing the JAK2 inhibitor CYT387, as well as pomalidomide. Additional areas of interest for MF therapy include the inhibition of histone/lysine deacetylases, hedgehog pathway inhibition, as well as combination strategies with JAK2 inhibitors.Keywords: myeloproliferative neoplasm, myelofibrosis, JAK2 inhibitorsMesa RABogenberger JMTibes RDove Medical PressarticleDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol 2012, Iss default, Pp 125-136 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Mesa RA Bogenberger JM Tibes R Recent developments in myelofibrosis
description	Raoul Tibes, James M Bogenberger, Ruben A MesaDivision of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USAAbstract: The myeloproliferative neoplasm of myelofibrosis (MF) is clinically constituted by individuals both with primary MF, as well as those that evolved from an antecedent polycythemia vera or essential thrombocythemia. Individuals presenting with MF have a heterogeneous phenotype which can involve significant constitutional symptoms (night sweats, fevers, weight loss, fatigue, variable but frequently problematic splenomegaly, and multifactorial cytopenias). These individuals clearly have decreased survival. Refinement of MF prognostic scores can distinguish from survival as poor as 16 months, to a median survival of 185 months. Sadly, although curative, allogeneic stem cell transplant still has sobering success rates for individuals of the standard ages for MF. Recent reports suggest less than half of patients will be alive at 3 years after allotransplant above the age of 60 years. The most important recent advancement in MF therapy has been the development of Janus kinase 2 (JAK2) inhibitors led by ruxolitinib, now Food and Drug Administration approved in the United States, and several other JAK2 inhibitors (in testing) including SAR302503, CYT387, and SB1518. In randomized, placebo-controlled studies, ruxolitinib was demonstrated to be superior for the improvement of splenomegaly and symptoms. These benefits are mirrored across other JAK2 inhibitors. Improving anemia remains an unmet need in MF and is currently being evaluated by clinical trials utilizing the JAK2 inhibitor CYT387, as well as pomalidomide. Additional areas of interest for MF therapy include the inhibition of histone/lysine deacetylases, hedgehog pathway inhibition, as well as combination strategies with JAK2 inhibitors.Keywords: myeloproliferative neoplasm, myelofibrosis, JAK2 inhibitors
format	article
author	Mesa RA Bogenberger JM Tibes R
author_facet	Mesa RA Bogenberger JM Tibes R
author_sort	Mesa RA
title	Recent developments in myelofibrosis
title_short	Recent developments in myelofibrosis
title_full	Recent developments in myelofibrosis
title_fullStr	Recent developments in myelofibrosis
title_full_unstemmed	Recent developments in myelofibrosis
title_sort	recent developments in myelofibrosis
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/080eaffa2590496f87c9e93a7f5c44ed
work_keys_str_mv	AT mesara recentdevelopmentsinmyelofibrosis AT bogenbergerjm recentdevelopmentsinmyelofibrosis AT tibesr recentdevelopmentsinmyelofibrosis
_version_	1718399854443495424

Recent developments in myelofibrosis

Ejemplares similares